IL10 and systemic lupus erythematosus: Immunostimulatory peptide autoantigens including those investigated here may, therefore, be pivotal in driving the disease process, raising the prospect that targeting antigen-specific T cells to actually produce less IL-10, and allowing the immune response to progress to full resolution, could be a viable route to reduce immune complex-mediated pathology in lupus.